Viral Inactivation Market, Size, Share, Opportunities and Forecast, 2020-2027

Global Viral Inactivation Market is segmented By Method (Solvent Detergent Method, Pasteurization, Others), By Product (Kits and Reagents, Services, Viral Inactivation Systems and Accessories), By Application (Vaccines and Therapeutics, Blood and Blood Products, Cellular and Gene Therapy Products, Tissues and Tissue Products, Stem Cell Products), By End-Users (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The "Global Viral Inactivation Market" is expected to grow at a high CAGR during the forecasting period (2020-2027).

Viral inactivation is the first of committed steps intended to improve the safety of biotherapeutic products. Viral inactivation testing is essential by regulatory authorities for investigational new drug (IND) submission and is mostly critical in process development for biologicals, including stem cell products, tissue and tissue products, blood and blood products, cellular and gene therapy products, and vaccine and therapeutics.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The key drivers for the market are rapid growth in pharmaceutical and biotechnology industries and robust trend of R&D investments in life sciences industry. Increasing chronic disease burden, rising number of new drug launches, and increasing government support for the pharmaceutical and biotechnology industries will propel the growth of this market.

Rising R&D Investments in the Life Sciences Industry

Investors have a keen interest in the life sciences industry and therefore, rising their investments in the life science industry. This interest has increased with the rising development of a vaccine and an R&D in the enhancement of effective treatment solutions for COVID-19, including other medical breakthroughs. This, in turn, is expected to create increased demand for solutions used in life science industry, including viral inactivation products and services.

Large Economic Burden of Chronic Diseases

Chronic diseases have substantial health and economic costs in the US. The economic burden of chronic diseases is continuously increasing across the globe, especially in low and middle-income economies, which lacks in developed healthcare infrastructure. With the rising economic burden of chronic diseases, the demand for viral inactivation will increase during the forecast period.

COVID-19 Impact Analysis

The COVID-19 has significantly impacted the market value of viral inactivation market globally. The demand for viral inactivation has increased with the rising inactivation the virus of COVID-19, severe acute respiratory syndrome. Therefore, a considerable growth has been estimated in the viral inactivation market in 2020.

Segmentation Analysis

Based on the application, the viral inactivation market has been classified into blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.

Vaccines and therapeutics will project the fastest growth in the market throughout the forecast period

Vaccines and therapeutics are expected to project the fastest rate in the global market due to rise in biologics production and an increase in government funding, majorly for the promotion of usage of biologics in the treatment of various chronic diseases. Moreover, the increasing R&D innovation in several applications, such as stem cell research and cellular & gene therapy has also been substantially contributing to the growth of the market.

Based on the product, the viral inactivation market has been classified into kits and reagents, services, and viral inactivation systems and accessories.

Kits and reagents segment dominated the global viral inactivation market in 2019

Kits and reagents segment accounted for the largest share in the global market in 2019. This dominance is attributed to the continuous usage of viral activation by pharmaceutical and biopharmaceutical companies. A wide range of kits and reagents are used in the process of viral activation. Therefore, owing to the increasing utilization of kits, consumables, and reagents in various end-use industries, the kits and reagents are the majorly used products in the viral activation market.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Based on geography, the study analyzes the viral inactivation market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominates the global viral inactivation market with the largest share in terms of value and volume globally, followed by Europe. The US dominated the North America viral inactivation market in 2019. The adoption of advanced technologies by the pharmaceuticals industry, well-developed healthcare infrastructure, rising number of drug approvals, are certain factors that is driving the growth of the market during the forecast period. Asia Pacific is expected to project a considerable CAGR in the market during the forecast period. The expansion of healthcare giants in the rapidly emerging markets, such as China, India, and others. These multinational companies are significantly investing in the healthcare sector in Asia Pacific region.

Competitive Landscape

The viral inactivation market is highly competitive, owing to the large presence of viral inactivation brands. The key viral inactivation players include Charles River Laboratories International, Inc., Clean Cells Inc., Danaher Corporation, Cerus Corporation, Parker Hannifin Corporation, Merck KGaA, Rad Source Technologies, Inc., Sartorius AG, SGS SA, and Wuxi Pharmatech (Cayman) Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the viral inactivation market.   

Sartorius AG

Overview: Sartorius AG was founded in 1870 and headquartered in Germany. The company operates as a supplier of pharmaceutical and laboratory equipment. The company has its own sales subsidiaries and production facilities in America, Europe, and Asia, in more than 110 countries. The company operates its business in two segments: bioprocess solutions and lab products and services. The bioprocess solutions segment provides solutions for biopharmaceutical manufacture such as single-use bags for cell cultivation, filters for sterilization of biopharmaceutical media, and storage of biopharmaceuticals, among others. The company is a leading international laboratory and process technology provider covering the segments of mechatronics and biotechnology. The company offers its solutions for four major applications: life science research, biopharmaceutical manufacturing, quality control & testing, and applied industries.  

Product Portfolio: The company's portfolio comprises Flexact for low pH virus inactivation, Flexact Modular, Sartopure GF Plus 1.2 and 0.65 μm filters, and Confidence Virus Clearance Validation Services.

Why Purchase the Report?

• Visualize the viral inactivation market segmentation composition by method, product, application, end-users, and region, highlighting the critical commercial assets and players.
• Identify commercial opportunities in the viral inactivation market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of viral inactivation market - level 3 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players.

The global viral inactivation market report would provide access to an approx. 68 market data tables, 63 figures, and 266 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Chemical
• Research Professionals
• Emerging Companies
• Manufacturers

Suggestions for Related Market Report:

• Global Rare Diseases Market
• Global Autoimmune Diseases Market
• Global Stem Cell Therapy Market

 

Table of Contents

1. Viral Inactivation Market Methodology and Scope

   1. Research Methodology
   2. Research Objective and Scope of the Report

2. Viral Inactivation Market – Market Definition and Overview

3. Viral Inactivation Market – Executive Summary

   1. Market Snippet by Method
   2. Market Snippet by Product
   3. Market Snippet by Application
   4. Market Snippet by End-Users
   5. Market Snippet by Region

4. Viral Inactivation Market – Market Dynamics

   1. Market Impacting Factors
      1. Drivers
         1. Increasing investment in life sciences industries
         2. Rise in government funding
      2. Restraints:
         1. High degree of market consolidation
      3. Opportunity
      4. Impact Analysis

5. Viral Inactivation Market – Industry Analysis

   1. Porter's Five Forces Analysis
   2. Supply Chain Analysis
   3. Value Chain Analysis
   4. PEST Analysis
   5. Pricing Analysis
   6. Regulatory Analysis
   7. Reimbursement Analysis
   8. Unmet Needs
   9. Patent Trends

6. Viral Inactivation Market – COVID-19 Analysis

   1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
   2. Pricing Dynamics Amid Covid-19
   3. Demand-Supply Spectrum
   4. Government Initiatives Related to the Market During Pandemic
   5. Manufacturers Strategic Initiatives
   6. Conclusion 

7. Viral Inactivation Market – By Method

   1. Introduction
   2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method Segment
   3. Market Attractiveness Index, By Method Segment
      1. Solvent Detergent Method*
         1. Introduction
         2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      2. Pasteurization
      3. Others

8. Viral Inactivation Market – By Product

   1. Introduction
   2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
   3. Market Attractiveness Index, By Product Segment
      1. Kits and Reagents*
         1. Introduction
         2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      2. Services
      3. Viral Inactivation Systems and Accessories

9. Viral Inactivation Market – By Application

   1. Introduction
   2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
   3. Market Attractiveness Index, By Application Segment
      1. Vaccines and Therapeutics*
         1. Introduction
         2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      2. Blood and Blood Products
      3. Cellular and Gene Therapy Products
      4. Tissues and Tissue Products
      5. Stem Cell Products

10. Viral Inactivation Market – By End-Users

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    3. Market Attractiveness Index, By End-Users
       1. Pharmaceutical and Biotechnology Companies*
          1. Introduction
          2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
       2. Contract Research Organizations
       3. Others

11. Viral Inactivation Market – By Region

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    3. Market Attractiveness Index, By Region
    4. North America
       1. Introduction
       2. Key Region-Specific Dynamics
       3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
       4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
       5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
       6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
       7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
          1. U.S.
          2. Canada
          3. Mexico
    5. Europe
       1. Introduction
       2. Key Region-Specific Dynamics
       3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
       4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
       5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
       6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
       7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
          1. Germany
          2. U.K.
          3. France
          4. Italy
          5. Spain
          6. Rest of Europe
    6. South America
       1. Introduction
       2. Key Region-Specific Dynamics
       3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
       4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
       5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
       6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
       7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
    7. Asia Pacific
       1. Introduction
       2. Key Region-Specific Dynamics
       3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
       4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
       5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
       6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
       7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
          1. China
          2. India
          3. Japan
          4. Australia
          5. Rest of Asia Pacific
    8. Middle East and Africa
       1. Introduction
       2. Key Region-Specific Dynamics
       3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
       4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
       5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
       6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
       7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. Viral Inactivation Market – Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis

13. Viral Inactivation Market- Company Profiles

    1. Charles River Laboratories International, Inc.*
       1. Company Overview
       2. Product Portfolio and Description
       3. Key Highlights
       4. Financial Overview
    2. Clean Cells Inc.
    3. Danaher Corporation
    4. Cerus Corporation
    5. Parker Hannifin Corporation
    6. Merck KGaA
    7. Rad Source Technologies, Inc.
    8. Sartorius AG
    9. SGS SA
    10. Wuxi Pharmatech (Cayman) Inc.
    11. Bioteke Corporation
    12. Hangzhou Qijulongyuan Medical Equipment
    13. Shenzhen Zijian Biotechnology Co., Ltd.
    14. Guangdong Poctman Life Technology Co., Ltd. (List Not Exhaustive)

14. Viral Inactivation Market – Premium Insights

15. Viral Inactivation Market – DataM Intelligence

    1. Appendix
    2. About Us and Services
    3. Contact Us